Wainua (Eplontersen) for Amyloidosis

Overview
Wainua is approved by the U.S. Food and Drug Administration (FDA) for the treatment of polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated amyloidosis in adults. This medication is specifically for individuals with this genetic condition, which leads to the buildup of abnormal proteins (amyloid) in organs and tissues. Wainua is also known by its drug name, eplontersen.

Wainua belongs to the drug category of transthyretin-directed antisense oligonucleotide. It works by targeting and reducing the production of transthyretin, a protein that forms amyloid deposits, thereby helping to manage the symptoms of polyneuropathy.

How do I take it?
Prescribing information states that Wainua is administered by subcutaneous (under the skin) injection, once per month. The injection should be given into the abdomen or upper thigh, though the back of the upper arm can be used if a health care provider or caregiver administers the injection. It is important to take Wainua exactly as prescribed by a health care provider.

Side effects
Common side effects of Wainua include decreased vitamin A levels and vomiting.

Rare but serious side effects may include ocular (eye-related) symptoms suggestive of vitamin A deficiency, which may require consultation with an ophthalmologist.

For more information about this treatment, visit:

Label: Wainua — Eplontersen Injection, Solution — DailyMed

Eplontersen injection — MedlinePlus